mavoglurant + nicotine

Mavoglurant (AFQ056) is a potent, selective, non-competitive antagonist of the metabotropic glutamate receptor 5 (mGluR5), originally developed by Novartis. This specific entry refers to the combination of mavoglurant and nicotine investigated for the treatment of nicotine dependence. The rationale for this combination is that mGluR5 antagonism can modulate the reward pathways associated with nicotine intake, potentially reducing cravings and withdrawal symptoms during smoking cessation. Clinical trials, including Phase 1 and Phase 2 studies, evaluated the safety and efficacy of this combination in healthy smokers, though development for this indication was ultimately terminated by Novartis.

Other names

AFQ056 + nicotine